Literature DB >> 11747043

Discounting for health effects in cost-benefit and cost-effectiveness analysis.

H Gravelle1, D Smith.   

Abstract

When health effects can be valued in monetary terms, as in cost-benefit analysis, they should be discounted at the same rate as costs. If health effects are measured in quantities (e.g. quality adjusted life years) as in cost-effectiveness analysis (CEA) and the value of health effects is increasing over time, discounting the volume of health effects at a lower rate than costs is a valid method of taking account of the increase in the future value of health effects. We show that the Keeler-Cretin paradox, often used as an argument against discounting health effects at a lower rate than costs, has no relevance for the choice of discount rate in CEA. We present individualistic and welfare models to argue that the rate of growth of the value of health effects is positive. The welfare model suggests that the value of health grows at a rate dependent on the rate of growth of the value of the direct effect of health on utility, the growth rate of income, the elasticity of the marginal utility of income and the extent to which individuals are insured against the income risks of ill health. Copyright 2001 John Wiley & Sons, Ltd.

Mesh:

Year:  2001        PMID: 11747043     DOI: 10.1002/hec.618

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  30 in total

Review 1.  Theoretical arguments for the discounting of health consequences: where do we go from here?

Authors:  Angelina Lazaro
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

2.  Perspective and desire in comparative effectiveness research: the relative unimportance of mere preferences, the central importance of context.

Authors:  Anthony J Culyer
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  The cost-effectiveness of rotavirus vaccination in Malawi.

Authors:  Stephen A Berry; Benjamin Johns; Chuck Shih; Andrea A Berry; Damian G Walker
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

4.  Towards a social discount rate for the economic evaluation of health technologies in Germany: an exploratory analysis.

Authors:  Mareike Schad; Jürgen John
Journal:  Eur J Health Econ       Date:  2010-12-19

5.  Nonparametric Benefit-Risk Assessment Using Marker Process in the Presence of a Terminal Event.

Authors:  Yifei Sun; Chiung-Yu Huang; Mei-Cheng Wang
Journal:  J Am Stat Assoc       Date:  2017-04-12       Impact factor: 5.033

Review 6.  Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases.

Authors:  Jasper M Bos; Philippe Beutels; Lieven Annemans; Maarten J Postma
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

7.  Discounting health effects in pharmacoeconomic evaluations: current controversies.

Authors:  J M Bos; Maarten J Postma; Lieven Annemans
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 8.  Economic evaluations: a new avenue of outcome assessment in spinal disorders.

Authors:  Nicole van der Roer; Norbert Boos; Maurits W van Tulder
Journal:  Eur Spine J       Date:  2005-12-01       Impact factor: 3.134

9.  Need for differential discounting of costs and health effects in cost effectiveness analyses.

Authors:  Werner B F Brouwer; Louis W Niessen; Maarten J Postma; Frans F H Rutten
Journal:  BMJ       Date:  2005-08-20

10.  Societal discounting of health effects in cost-effectiveness analyses: the influence of life expectancy.

Authors:  Suzanne Polinder; Willem Jan Meerding; Job van Exel; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.